Our free daily oncology focused e-news service.
Subscribe» | Search Archives»
(Threshold) Sept 22, 2014 - Threshold Pharmaceuticals, Inc. today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS).
read corporate press release »
(PharmaTimes UK) Sept 22, 2014 - Biotechnology giant Amgen has filed its investigational cancer immunotherapy blinatumomab in the US for the treatment of certain forms of acute lymphoblastic leukaemia (ALL).
read article »
News Story Commentary By Academic and Community Oncologists
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
Bayer Biopharmaceuticals, Inc. has posted 20 new jobs.
Ipsen Biopharmaceuticals, Inc. has posted over 50 new jobs.
Novocure has posted 4 jobs.